In this issue:
Weekends-off efavirenz-based ART in young people
Australian HIV PrEP clinical guidelines
Dolutegravir-rilpivirine maintains HIV-1 suppression
A single-tablet darunavir-based once-daily regimen for HIV-1
Meeting the UNAIDS 90-90-90 targets in NSW, Australia
Immediate ART initiation: a low risk of acquired drug resistance
Low serum albumin predicts serious non-AIDS events
Residual replication rare after dolutegravir intensification
Retain quarterly HIV testing for high-risk MSM
Lopinavir/r monotherapy vs EFV/FTC/TDF in virologically suppressed patients
Please login below to download this issue (PDF)